Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
Atrial fibrillation and renal dysfunction often coexist, each disorder may predispose to the other and contribute to worsening prognosis. Both atrial fibrillation and chronic kidney disease are associated with increased risk of stroke and thromboembolic complications. Oral anticoagulation for stroke...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2021-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2389 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227576858378240 |
|---|---|
| author | Z. D. Kobalava A. A. Shavarov M. V. Vatsik-Gorodetskaya |
| author_facet | Z. D. Kobalava A. A. Shavarov M. V. Vatsik-Gorodetskaya |
| author_sort | Z. D. Kobalava |
| collection | DOAJ |
| description | Atrial fibrillation and renal dysfunction often coexist, each disorder may predispose to the other and contribute to worsening prognosis. Both atrial fibrillation and chronic kidney disease are associated with increased risk of stroke and thromboembolic complications. Oral anticoagulation for stroke prevention is therefore recommended in patients with atrial fibrillation and decreased renal function. Each direct oral anticoagulant has unique pharmacologic properties of which clinician should be aware to optimally manage patients. The doses of direct oral anticoagulants require adjustment for renal function. There is debate regarding which equation, the Chronic Kidney Disease Epidemiology (CKD-EPI) equation vs. the Cockcroft-Gault equation, should be used to estimate glomerular filtration rate in patients with atrial fibrillation treated with direct oral anticoagulants. Our review tries to find arguments for benefit of direct oral anticoagulants in patients with renal dysfunction. |
| format | Article |
| id | doaj-art-5fe3d4e05b8c4b338b8f42a0bbe88e77 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2021-03-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-5fe3d4e05b8c4b338b8f42a0bbe88e772025-08-23T10:00:33ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532021-03-01171627210.20996/1819-6446-2021-02-031841Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal DysfunctionZ. D. Kobalava0A. A. Shavarov1M. V. Vatsik-Gorodetskaya2Peoples Friendship University of Russia (RUDN University)Peoples Friendship University of Russia (RUDN University)V.V. Vinogradov City Clinical HospitalAtrial fibrillation and renal dysfunction often coexist, each disorder may predispose to the other and contribute to worsening prognosis. Both atrial fibrillation and chronic kidney disease are associated with increased risk of stroke and thromboembolic complications. Oral anticoagulation for stroke prevention is therefore recommended in patients with atrial fibrillation and decreased renal function. Each direct oral anticoagulant has unique pharmacologic properties of which clinician should be aware to optimally manage patients. The doses of direct oral anticoagulants require adjustment for renal function. There is debate regarding which equation, the Chronic Kidney Disease Epidemiology (CKD-EPI) equation vs. the Cockcroft-Gault equation, should be used to estimate glomerular filtration rate in patients with atrial fibrillation treated with direct oral anticoagulants. Our review tries to find arguments for benefit of direct oral anticoagulants in patients with renal dysfunction.https://www.rpcardio.online/jour/article/view/2389atrial fibrillationglomerular filtration rateamiodaronedabigatranrivaroxabanapixaban |
| spellingShingle | Z. D. Kobalava A. A. Shavarov M. V. Vatsik-Gorodetskaya Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction Рациональная фармакотерапия в кардиологии atrial fibrillation glomerular filtration rate amiodarone dabigatran rivaroxaban apixaban |
| title | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction |
| title_full | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction |
| title_fullStr | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction |
| title_full_unstemmed | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction |
| title_short | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction |
| title_sort | direct oral anticoagulants in patients with atrial fibrillation and renal dysfunction |
| topic | atrial fibrillation glomerular filtration rate amiodarone dabigatran rivaroxaban apixaban |
| url | https://www.rpcardio.online/jour/article/view/2389 |
| work_keys_str_mv | AT zdkobalava directoralanticoagulantsinpatientswithatrialfibrillationandrenaldysfunction AT aashavarov directoralanticoagulantsinpatientswithatrialfibrillationandrenaldysfunction AT mvvatsikgorodetskaya directoralanticoagulantsinpatientswithatrialfibrillationandrenaldysfunction |